Cargando…
A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder
OBJECTIVE: Traditional metal alloy occluders for the closure of patent foramen ovale (PFO) may be associated with some potential complications, and may restrict the trans-septal access to the left atrium for future treatment of left-sided heart disease. Increasing attention has been paid to novel bi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110699/ https://www.ncbi.nlm.nih.gov/pubmed/35592394 http://dx.doi.org/10.3389/fcvm.2022.849459 |
_version_ | 1784709158084280320 |
---|---|
author | Du, Yajuan Xie, Hang Shao, Hui Cheng, Gesheng Wang, Xingye He, Xumei Lan, Beidi He, Lu Zhang, Yushun |
author_facet | Du, Yajuan Xie, Hang Shao, Hui Cheng, Gesheng Wang, Xingye He, Xumei Lan, Beidi He, Lu Zhang, Yushun |
author_sort | Du, Yajuan |
collection | PubMed |
description | OBJECTIVE: Traditional metal alloy occluders for the closure of patent foramen ovale (PFO) may be associated with some potential complications, and may restrict the trans-septal access to the left atrium for future treatment of left-sided heart disease. Increasing attention has been paid to novel biodegradable occluders (NBOs) to achieve PFO closure. We aimed to evaluate the role of transesophageal echocardiography (TEE) in the diagnostic and anatomical evaluation of PFO, as well as in the Post-procedural assessment after transcatheter closure with a NBO. METHODS: We conducted a prospective, single-center clinical study of 44 patients who were diagnosed with PFO by contrast transthoracic echocardiography (c-TTE) and TEE from June 2019 to June 2020. All patients underwent PFO occlusion with NBO under TTE guidance. Follow-up was performed at 2 days and 3 months after the procedure with TTE, and at 6 months and 1 year after the procedure with c-TTE, TTE, and TEE. RESULTS: Interventional treatment was successfully performed in all patients. The left and right sides of the occluder device disc were significantly reduced at 3, 6, and 12 months compared to 2 days after the procedure (all P < 0.01), and decreased gradually. The thickness was significantly reduced at 12 months compared to the first three time points (all P < 0.01). Thrombus was found on the surface of the occluder device in three patients (6.4%) at 3 and 6 months after occlusion. At 6 months after procedure, there were 3 (6.8%) cases of extensive residual right-to-left shunt (RLS), 2 (4.5%) cases of moderate shunt, and 7 (15.9%) cases of small shunts. One year after procedure, 2 (4.5%) cases had a extensive residual shunt, 6 (13.6%) cases of small shunts were confirmed to originate from pulmonary veins by TEE, and the PFO-RLS occlusion rate reached 95.5%. CONCLUSION: This study demonstrates the feasibility, safety, and effectiveness of NBO for the closure of PFO in humans, with a high rate of complete shunt closure. Accurate TEE assessment of the PFO anatomy before closure with NBO is important to ensure that the procedure remains safe and effective. Furthermore, TEE plays a crucial role in the Post-procedure follow-up. |
format | Online Article Text |
id | pubmed-9110699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91106992022-05-18 A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder Du, Yajuan Xie, Hang Shao, Hui Cheng, Gesheng Wang, Xingye He, Xumei Lan, Beidi He, Lu Zhang, Yushun Front Cardiovasc Med Cardiovascular Medicine OBJECTIVE: Traditional metal alloy occluders for the closure of patent foramen ovale (PFO) may be associated with some potential complications, and may restrict the trans-septal access to the left atrium for future treatment of left-sided heart disease. Increasing attention has been paid to novel biodegradable occluders (NBOs) to achieve PFO closure. We aimed to evaluate the role of transesophageal echocardiography (TEE) in the diagnostic and anatomical evaluation of PFO, as well as in the Post-procedural assessment after transcatheter closure with a NBO. METHODS: We conducted a prospective, single-center clinical study of 44 patients who were diagnosed with PFO by contrast transthoracic echocardiography (c-TTE) and TEE from June 2019 to June 2020. All patients underwent PFO occlusion with NBO under TTE guidance. Follow-up was performed at 2 days and 3 months after the procedure with TTE, and at 6 months and 1 year after the procedure with c-TTE, TTE, and TEE. RESULTS: Interventional treatment was successfully performed in all patients. The left and right sides of the occluder device disc were significantly reduced at 3, 6, and 12 months compared to 2 days after the procedure (all P < 0.01), and decreased gradually. The thickness was significantly reduced at 12 months compared to the first three time points (all P < 0.01). Thrombus was found on the surface of the occluder device in three patients (6.4%) at 3 and 6 months after occlusion. At 6 months after procedure, there were 3 (6.8%) cases of extensive residual right-to-left shunt (RLS), 2 (4.5%) cases of moderate shunt, and 7 (15.9%) cases of small shunts. One year after procedure, 2 (4.5%) cases had a extensive residual shunt, 6 (13.6%) cases of small shunts were confirmed to originate from pulmonary veins by TEE, and the PFO-RLS occlusion rate reached 95.5%. CONCLUSION: This study demonstrates the feasibility, safety, and effectiveness of NBO for the closure of PFO in humans, with a high rate of complete shunt closure. Accurate TEE assessment of the PFO anatomy before closure with NBO is important to ensure that the procedure remains safe and effective. Furthermore, TEE plays a crucial role in the Post-procedure follow-up. Frontiers Media S.A. 2022-05-03 /pmc/articles/PMC9110699/ /pubmed/35592394 http://dx.doi.org/10.3389/fcvm.2022.849459 Text en Copyright © 2022 Du, Xie, Shao, Cheng, Wang, He, Lan, He and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Du, Yajuan Xie, Hang Shao, Hui Cheng, Gesheng Wang, Xingye He, Xumei Lan, Beidi He, Lu Zhang, Yushun A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder |
title | A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder |
title_full | A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder |
title_fullStr | A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder |
title_full_unstemmed | A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder |
title_short | A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder |
title_sort | prospective, single-center, phase i clinical trial to evaluate the value of transesophageal echocardiography in the closure of patent foramen ovale with a novel biodegradable occluder |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110699/ https://www.ncbi.nlm.nih.gov/pubmed/35592394 http://dx.doi.org/10.3389/fcvm.2022.849459 |
work_keys_str_mv | AT duyajuan aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT xiehang aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT shaohui aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT chenggesheng aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT wangxingye aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT hexumei aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT lanbeidi aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT helu aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT zhangyushun aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT duyajuan prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT xiehang prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT shaohui prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT chenggesheng prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT wangxingye prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT hexumei prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT lanbeidi prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT helu prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder AT zhangyushun prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder |